Low immediate postoperative serum-cortisol nadir predicts the short-term, but not long-term, remission after pituitary surgery for Cushing's disease

BMC Endocr Disord. 2015 Oct 25:15:62. doi: 10.1186/s12902-015-0055-9.

Abstract

Background: Cushing's disease is an ACTH-producing pituitary adenoma, and the primary treatment is microscopic or endoscopic transsphenoidal selective adenectomy. The aims of the present study were to evaluate whether the early postoperative S-cortisol level can serve as a prognostic marker for short- and long-term remission, and retrospectively review our own short and long term results after surgery for Cushing's disease.

Methods: This single centre, retrospective study consists of 19 consecutive patients with Cushing's disease who underwent transsphenoidal surgery. S-cortisol was measured every 6 h after the operation without any glucocorticoid replacement. We have follow-up on all patients, with a mean follow-up of 68 months.

Results: At the three-month follow-up, 16 patients (84 %) were in remission; at 12 months, 18 (95 %) were in remission and at the final follow-up (mean 68 months), 13 (68 %) were in remission. Five-years recurrence rate was 26 %. The mean postoperative S-cortisol nadir was significantly lower in the group of patients in remission than in the non-remission group at 3 months, but there was no difference between those in long-term remission compared to those in long-term non-remission. The optimal cut-off value for classifying 3-month remission was 74 nmol/l.

Conclusion: We achieved a 95 % 1-year remission rate with transsphenoidal surgery for Cushing's disease in this series of consecutive patients. However, the 5-year recurrence rate was 26 %, showing the need for regular clinical and biochemical controls in this patient group. The mean postoperative serum-cortisol nadir was significantly lower in patients in remission at 3 months compared to patients not in remission at 3 months, but a low postoperative S-cortisol did not predict long-term remission.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Biomarkers / blood*
  • Female
  • Follow-Up Studies
  • Humans
  • Hydrocortisone / blood*
  • Male
  • Middle Aged
  • Pituitary ACTH Hypersecretion / blood*
  • Pituitary ACTH Hypersecretion / complications
  • Pituitary ACTH Hypersecretion / surgery
  • Pituitary Diseases / blood*
  • Pituitary Diseases / complications
  • Pituitary Diseases / surgery
  • Postoperative Complications*
  • Predictive Value of Tests
  • Recurrence
  • Remission Induction
  • Retrospective Studies
  • Young Adult

Substances

  • Biomarkers
  • Hydrocortisone